Literature DB >> 32828292

RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.

Nobuhiro Tsuruta1, Kenji Tsuchihashi1, Hirofumi Ohmura1, Kyoko Yamaguchi1, Mamoru Ito1, Hiroshi Ariyama1, Hitoshi Kusaba1, Koichi Akashi1, Eishi Baba2.   

Abstract

Fat mass and obesity-associated protein (FTO) is an enzyme that demethylates N6-methyladenosine (m6A), the most abundant RNA modifications in a cell. The upregulated expression of FTO promotes the progression of various types of cancer by modulating cell-intrinsic genes which relate to malignant potential. However, the impact of FTO on the expression of immune-checkpoint molecules in the tumor cells, which are important for immune escape, has not been well understood. We examined the relevance of FTO to programmed cell death-ligand 1 (PD-L1) expression in colon cancer cells. HCT-116 cells showed high expression of both FTO and PD-L1 proteins. The knockdown of FTO by small interfering RNA decreased mRNA and protein levels of PD-L1 in HCT-116 cells. To elucidate the underlying mechanism by which FTO regulates the expression of PD-L1, we depleted FTO in HCT-116 in the presence of IFN-γ, which is a major stimulus to upregulate PD-L1 expression. Depletion of FTO reduced PD-L1 expression in an IFN-γ signaling-independent manner. RNA immunoprecipitation assay revealed the m6A modification of the PD-L1 mRNA and the binding of FTO to the PD-L1 mRNA in HCT-116. Taken together, our results indicated that FTO could regulate PD-L1 expression in colon cancer cells and provides new insights into the regulation of PD-L1 expression by RNA modification.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Colon cancer; Fat mass and obesity-associated protein; N6-methyladenosine; Programmed cell death-ligand 1

Mesh:

Substances:

Year:  2020        PMID: 32828292     DOI: 10.1016/j.bbrc.2020.06.153

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors:  Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal:  Nat Rev Clin Oncol       Date:  2022-02-07       Impact factor: 66.675

Review 2.  One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.

Authors:  Xianfeng Ouyang; Yuping Gong
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

Review 3.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 4.  Emerging role of RNA modification N6-methyladenosine in immune evasion.

Authors:  Xin Lou; Juan-Juan Wang; Ya-Qing Wei; Jin-Jin Sun
Journal:  Cell Death Dis       Date:  2021-03-19       Impact factor: 8.469

Review 5.  Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.

Authors:  Hao Zhang; Ziyu Dai; Wantao Wu; Zeyu Wang; Nan Zhang; Liyang Zhang; Wen-Jing Zeng; Zhixiong Liu; Quan Cheng
Journal:  J Exp Clin Cancer Res       Date:  2021-06-04

6.  METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer.

Authors:  Weijun Wan; Xiang Ao; Quan Chen; Yang Yu; Luoquan Ao; Wei Xing; Wei Guo; Xiaofeng Wu; Chengxiu Pu; Xueting Hu; Zhan Li; Mengwei Yao; Donglin Luo; Xiang Xu
Journal:  Mol Cancer       Date:  2022-02-23       Impact factor: 27.401

Review 7.  Targeting the RNA m6A modification for cancer immunotherapy.

Authors:  Xinxin Li; Shoubao Ma; Youcai Deng; Ping Yi; Jianhua Yu
Journal:  Mol Cancer       Date:  2022-03-16       Impact factor: 27.401

Review 8.  RNA N6 -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential.

Authors:  Zhihui Zhang; Chaoqi Zhang; Yuejun Luo; Guochao Zhang; Peng Wu; Nan Sun; Jie He
Journal:  Clin Transl Med       Date:  2021-09

Review 9.  N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.

Authors:  Liting Guo; Hui Yang; Chenfei Zhou; Yan Shi; Lei Huang; Jun Zhang
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

10.  N6-Methylandenosine-Related lncRNAs in Tumor Microenvironment Are Potential Prognostic Biomarkers in Colon Cancer.

Authors:  Hongliang Zhang; Lei Zhao; Songyan Li; Jing Wang; Cong Feng; Tanshi Li; Xiaohui Du
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.